Abstract
Processing of antigens within antigen presenting cells (APCs) is necessary for an immune response. Two pathways exist to present antigens to T cells: the major histocompatibility complex class I (MHC I) pathway to activate cytotoxic T cells (CTLs) and the MHC II route to stimulate T helper cells (Ths). Prior to efficient antigen presentation to MHC II, antigens have to be proteolytically degraded by proteases, the cathepsins, inside the endocytic compartment of APCs. Cathepsins process both antigens and self-antigens to antigenic peptides; the latter are critical for autoimmunity. Remarkably, distribution, substrate specificity, and function of cathepsins located in the antigen processing machinery depend on the cell type, primary or cultured cells, or species analyzed. However, a precise understanding of the antigen processing and presentation machinery is needed to generate specific immune modulators since the MHC antigen- processing pathway is subsequently regulated during tumorigenesis, infection, or autoimmunity. In this review, the latest finding regarding function and regulation of the MHC II proteolytic machinery and its possible target for immunomodulation will be discussed.
Keywords: Antigen processing and presentation, major histocompatibility complex, cathepsin, cathepsin-specific inhibitors, dendritic cells, B cells, immunomodulation.
Current Pharmaceutical Design
Title:Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation
Volume: 19 Issue: 6
Author(s): Timo Burster
Affiliation:
Keywords: Antigen processing and presentation, major histocompatibility complex, cathepsin, cathepsin-specific inhibitors, dendritic cells, B cells, immunomodulation.
Abstract: Processing of antigens within antigen presenting cells (APCs) is necessary for an immune response. Two pathways exist to present antigens to T cells: the major histocompatibility complex class I (MHC I) pathway to activate cytotoxic T cells (CTLs) and the MHC II route to stimulate T helper cells (Ths). Prior to efficient antigen presentation to MHC II, antigens have to be proteolytically degraded by proteases, the cathepsins, inside the endocytic compartment of APCs. Cathepsins process both antigens and self-antigens to antigenic peptides; the latter are critical for autoimmunity. Remarkably, distribution, substrate specificity, and function of cathepsins located in the antigen processing machinery depend on the cell type, primary or cultured cells, or species analyzed. However, a precise understanding of the antigen processing and presentation machinery is needed to generate specific immune modulators since the MHC antigen- processing pathway is subsequently regulated during tumorigenesis, infection, or autoimmunity. In this review, the latest finding regarding function and regulation of the MHC II proteolytic machinery and its possible target for immunomodulation will be discussed.
Export Options
About this article
Cite this article as:
Burster Timo, Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation, Current Pharmaceutical Design 2013; 19 (6) . https://dx.doi.org/10.2174/1381612811319060005
DOI https://dx.doi.org/10.2174/1381612811319060005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Novel Alkyl Pyridine Platinum Complexes on Apoptosis in Ishikawa Endometrial Cancer Cells
Medicinal Chemistry Modulation of Protein-Protein Interactions by Stabilizing/Mimicking Protein Secondary Structure Elements
Current Topics in Medicinal Chemistry Liposomal Nanotechnology for Cancer Theranostics
Current Medicinal Chemistry 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Intestinal Targeting of Drugs: Rational Design Approaches and Challenges
Current Topics in Medicinal Chemistry New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Graphical Abstracts:
Anti-Cancer Agents in Medicinal Chemistry Isolation of Bioactive Natural Products from Myxomycetes
Medicinal Chemistry Activation of Integrin β1 Mediates the Increased Malignant Potential of Ovarian Cancer Cells Exerted by Inflammatory Cytokines
Anti-Cancer Agents in Medicinal Chemistry Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Immunoglobulin G Expression and its Potential Role in Primary and Metastatic Breast Cancers
Current Molecular Medicine Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
Current Medicinal Chemistry Application of Diffusion Weighted Imaging in Prostate Cancer Bone Metastasis: Detection and Therapy Evaluation
Anti-Cancer Agents in Medicinal Chemistry Screening of Photosynthetic Pigments for Herbicidal Activity with a New Computational Molecular Approach
Combinatorial Chemistry & High Throughput Screening Anti-Interleukin-6 Therapy for Crohns Disease
Current Pharmaceutical Design DNA Methyltransferase Inhibitors and their Therapeutic Potential
Current Topics in Medicinal Chemistry Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Oxidative stress in carcinogenesis: new synthetic compounds with dual effects upon free radicals and cancer.
Current Medicinal Chemistry